TB/FLU-04L
Candidate Overview
Based on the attenuated influenza strain Flu NS106/ESAT-6_Ag85A expressing mycobacterial antigens Esat-6 and Ag85A.
Sponsor / Lead Developer: Research Institute for Biological Safety Problems (RIBSP)
Development partner(s): Smorodintsev Research Institute of Influenza (SRII)
Clinical Trials
COMPLETED TRIALS |
|
| Registry Number | NCT02501421 |
| Clinical Trial Phase | Phase 1 |
| Status | Completed |
| Primary endpoint(s) for this clinical trial | Safety |
| Target population(s) for clinical trial | Adults |
Related Publications
- Preclinical Safety Evaluation: Acute and Repeated-Dose Toxicity of a New Intranasal Recombinant Vector Vaccine TB/FLU-04L Against Tuberculosis (Drug Res (Stuttg), 2022)
- A New Intranasal Influenza Vector-Based Vaccine TB/FLU-04L Against Tuberculosis: Preclinical Safety Studies (Drug Res (Stuttg), 2022)
Additional Information
Phase 2a trial postponed until additional preclinical reproductive toxicology studies are done.